Ulrich Trechsel

TL;DR: Zoledronic acid infusions given at intervals of up to one year produce effects on bone turnover and bone density as great as those achieved with daily oral dosing with bisphosphonates with proven efficacy against fractures, suggesting that an annual infusion of zoledronic Acid might be an effective treatment for postmenopausal osteoporosis.

TL;DR: Intermittent intravenous zoledronic acid affected BMD to about the same degree as daily oral bisphosphonate therapy in these postmenopausal women, and Conceivably an annual infusion might effectively control post menopausal osteoporosis.

TL;DR: This study showed that zoledronic acid 4 mg once-yearly was well tolerated and effective in reducing biomarkers over 5 years, and detailed analysis of bone marker changes suggests that this drug regimen causes insufficient reduction of remodelling activity in one third of patients.

TL;DR: Lumiracoxib was well tolerated in patients with knee osteoarthritis and WOMAC™ total and subscales improved for both active treatments versus placebo except for difficulty in performing daily activities, for which celecoxib just failed to achieve significance.

TL;DR: Bisphosphonates can be used with satisfactory results for prolonged inhibition of bone resorption in conditions of abnormally increased bone turnover, e.g. osteoporosis, by intermittent administration as discussed by the authors.